Skip to main content
. Author manuscript; available in PMC: 2011 Mar 1.
Published in final edited form as: Lab Invest. 2010 May 10;90(9):1325–1338. doi: 10.1038/labinvest.2010.99

Figure 1.

Figure 1

Figure 1

Figure 1

Resveratrol renders cholangiocarcinoma cells, but not non-malignant cholangiocytes, more susceptible to chemotherapeutic agents in vitro. Cholangiocarcinoma cells (Mz-ChA-1, SG231, CCLP-1 and HuCCT-1) and non-malignant human cholangiocytes (H69) were treated with resveratrol (Resv; 20 μM) prior to the addition of 5-FU (30 μM; A), Mitomycin C (Mito C; 5 μM; B), or Gemcitabine (Gemc; 30 μM; C) for 48hr. Cell proliferation was assessed using an MTS cell proliferation assay. Data are expressed as fold change in proliferation (average ± SEM, n=7). The * denotes significance (p<0.05) compared to basal, and the # denotes significance (p<0.05) compared to the chemotherapy treatment alone.